- Conditions
- Schizophrenia
- Interventions
- LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine
- Drug
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 42
- States / cities
- Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Psychiatry
- Interventions
- Not listed
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
- Interventions
- Not listed
- Lead sponsor
- Genelex Corporation
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
- Conditions
- Schizophrenia
- Interventions
- paliperidone, risperidone, haloperidole, perphenazine, aripiprazole, quetiapine, paliperidone palmitate, olanzapine
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 55
- States / cities
- Bullhead City, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 52 more
- Conditions
- Bipolar I Disorder
- Interventions
- Injectable Risperidone (Consta) or oral antipsychotic
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 4
- States / cities
- Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole, Risperidone
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Glen Oaks, New York
- Conditions
- Schizophrenia Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
- Interventions
- Plasma NDE miRNA Sequencing, Whole Genome Sequencing
- Diagnostic Test · Genetic
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Glen Oaks, New York
- Conditions
- Schizophrenia, Psychotic Disorders
- Interventions
- Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 337 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 34
- States / cities
- Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
- Conditions
- Schizophrenia
- Interventions
- LY2140023, Placebo, Standard of Care
- Drug
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole, Risperidone, Healthy volunteers
- Drug · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Butner, North Carolina
- Conditions
- Weight Gain, Autism Spectrum Disorder, Medication Side Effect
- Interventions
- Comparison of Risperidone and Aripiprazole
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee